medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2011, Number 4

<< Back Next >>

Biotecnol Apl 2011; 28 (4)

Retroviral integration: A critical step in viral life cycle suitable for drug intervention

Fernández-Ortega C, Ramírez-Suárez A, Paneque-Guerrero T, Casillas-Casanova D

Language: English
References: 32
Page: 255-260
PDF size: 160.50 Kb.


ABSTRACT

Retroviral integration is an essential stage in the life cycle of retroviruses. Viruses need to insert their DNA into the chromosomal DNA of the host cells. Retroviral integration is a complex process which involves viral and host proteins and requires the movement of the retroviral DNA from the cytoplasm to the nucleus. The viral integrase is a key enzyme in this process that catalyzes two reactions: 3´ processing of viral DNA that take place in the cytoplasm following reverse transcription and the strand transfer that inserts viral DNA in a host cell chromosome. Development of a successful treatment for the human immunodeficiency virus (HIV) infection using the strand transfer inhibitor, Raltegravir, has demonstrated that retroviral integration is a suitable step for drug intervention. Different types of inhibitors targeting HIV integrase or any of the other components of the retroviral integration process are currently being designed or developed. This work contains a summary of the retroviral integration process as well as, many of the latest advances in this topic which were exposed at the recently held IVth International Meeting on Retroviral Integration.


REFERENCES

  1. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011; 343:d6016.

  2. Arhel N, Kirchhoff F. Host proteins involved in HIV infection: new therapeutic targets. Biochim Biophys Acta. 2010; 1802(3):313-21.

  3. Ramkumar K, Neamati N. Raltegravir: The evidence of its therapeutic value in HIV-1 infection. Core Evid. 2010;4:131-47.

  4. Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature. 2010;468(7321):326-9.

  5. Lewinski MK, Bushman FD. Retroviral DNA integration--mechanism and consequences. Adv Genet. 2005;55:147-81.

  6. Hughes SH, Shank PR, Spector DH, Kung HJ, Bishop JM, Varmus HE, et al. Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. Cell. 1978;15(4):1397-410.

  7. Vincent KA, York-Higgins D, Quiroga M, Brown PO. Host sequences flanking the HIV provirus. Nucleic Acids Res. 1990; 18(20):6045-7.

  8. Craigie R, Fujiwara T, Bushman F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell. 1990;62(4):829-37.

  9. Fujiwara T, Mizuuchi K. Retroviral DNA integration: structure of an integration intermediate. Cell. 1988;54(4):497-504.

  10. Balakrishnan M, Jonsson CB. Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. J Virol. 1997;71(2):1025-35.

  11. Bushman FD, Craigie R. Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro. J Virol. 1990;64(11):5645-8.

  12. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 1994;266(5193):2002-6.

  13. Lee MS, Craigie R. Protection of retroviral DNA from autointegration: involvement of a cellular factor. Proc Natl Acad Sci USA. 1994;91(21):9823-7.

  14. Farnet CM, Bushman FD. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 1997;88(4):483-92.

  15. Rakotobe D, Violot S, Hong SS, Gouet P, Boulanger P. Mapping of immunogenic and protein-interacting regions at the surface of the seven-bladed beta-propeller domain of the HIV-1 cellular interactor EED. Virol J. 2008;5:32.

  16. Cereseto A, Manganaro L, Gutierrez MI, Terreni M, Fittipaldi A, Lusic M, et al. Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBO J. 2005;24(17):3070-81.

  17. Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 2006;22(7):388-95.

  18. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, et al. An essential role for LEDGF/p75 in HIV integration. Science. 2006;314(5798):461-4.

  19. Singh DP, Ohguro N, Chylack LT Jr, Shinohara T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Invest Ophthalmol Vis Sci. 1999;40(7):1444-51.

  20. Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 1998;17(22):6723-9.

  21. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem. 2003; 278(1):372-81.

  22. Cherepanov P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res. 2007;35(1):113-24.

  23. Vandegraaff N, Devroe E, Turlure F, Silver PA, Engelman A. Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication. Virology. 2006;346(2):415-26.

  24. Engelman A, Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008; 4(3):e1000046.

  25. Kotova S, Li M, Dimitriadis EK, Craigie R. Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy. J Mol Biol. 2010;399(3):491-500.

  26. Kessl JJ, Li M, Ignatov M, Shkriabai N, Eidahl JO, Feng L, et al. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res. 2011; 39(20):9009-22.

  27. Albanese A, Arosio D, Terreni M, Cereseto A. HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery. PLoS One. 2008; 3(6):e2413.

  28. Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci USA. 2011;108(24):9975-80.

  29. Arriagada G, Muntean LN, Goff SP. SUMO-interacting motifs of human TRIM5alpha are important for antiviral activity. PLoS Pathog. 2011;7(4):e1002019.

  30. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565-72.

  31. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol. 2010; 6(6):442-8.

  32. Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M. Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. Nat Med. 2010;16(3):329-33.




2020     |     www.medigraphic.com